Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

  1. Taxonera, C.
  2. Rodríguez, C.
  3. Bertoletti, F.
  4. Menchén, L.
  5. Arribas, J.
  6. Sierra, M.
  7. Arias, L.
  8. Martínez-Montiel, P.
  9. Juan, A.
  10. Iglesias, E.
  11. Algaba, A.
  12. Manceñido, N.
  13. Rivero, M.
  14. Barreiro-De Acosta, M.
  15. López-Serrano, P.
  16. Argüelles-Arias, F.
  17. Gutierrez, A.
  18. Busquets, D.
  19. Gisbert, J.P.
  20. Olivares, D.
  21. Calvo, M.
  22. Alba, C.
  23. García-Planella, E.
  24. Cabriada, J.L.
  25. López-Sanroman, A.
  26. Sicilia, B.
  27. Domènech, E.
  28. Olivares, S.
  29. Bermejo, F.
  30. Chaparro, M.
  31. Pérez-Calle, J.L.
  32. Muñoz, C.
  33. Higuera, R.
  34. Merino, O.
  35. Show all authors +
Journal:
Inflammatory Bowel Diseases

ISSN: 1536-4844 1078-0998

Year of publication: 2017

Volume: 23

Issue: 8

Pages: 1394-1402

Type: Article

DOI: 10.1097/MIB.0000000000001144 GOOGLE SCHOLAR

Sustainable development goals